Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma
Status:
Unknown status
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
In this study with a modified 3+3 dose finding design, a safe and tolerable dose of TKI258 in
patients with relapsed glioblastoma should be established.